1:02 PM
 | 
Mar 02, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA reviewing Mallinckrodt's neonatal jaundice candidate

Mallinckrodt plc (NYSE:MNK) said FDA accepted for review an NDA for stannsoporfin to...

Read the full 45 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >